Last 47 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 51.06 | 26.84 | — | 21.13 | 14.87 | 26.36 | 13.58 | 26.21 | 30.23 | 27.95 | 53.34 | 35.05 | 46.66 | 26.61 | 36.29 | 30.72 | 28.92 | 44.29 | 83.18 | 29.47 | 62.07 |
| — | +1.8% | — | -19.4% | -50.8% | -5.7% | -74.5% | -25.2% | -35.2% | +5.0% | +47.0% | +14.1% | +61.3% | -39.9% | -56.4% | +4.3% | -53.4% | — | — | -38.5% | +167.9% | |
| P/S Ratio | 3.57 | 2.60 | 1.80 | 2.78 | 1.75 | 2.78 | 2.38 | 2.82 | 2.96 | 3.17 | 3.20 | 3.27 | 3.62 | 3.51 | 3.48 | 3.30 | 3.21 | 3.33 | 3.06 | 2.62 | 3.86 |
| — | -6.3% | -24.2% | -1.3% | -40.7% | -12.5% | -25.6% | -13.9% | -18.2% | -9.6% | -8.2% | -0.8% | +12.8% | +5.5% | +13.6% | +25.9% | -16.9% | -10.4% | -51.2% | -58.7% | -27.3% | |
| P/B Ratio | 6.22 | 4.22 | 3.14 | 4.14 | 2.70 | 4.04 | 3.83 | 4.33 | 4.65 | 4.71 | 4.57 | 4.66 | 5.15 | 5.06 | 5.18 | 5.19 | 5.24 | 4.52 | 4.33 | 3.73 | 5.30 |
| — | +4.3% | -18.1% | -4.5% | -41.9% | -14.2% | -16.2% | -7.1% | -9.7% | -6.8% | -11.8% | -10.2% | -1.6% | +11.9% | +19.6% | +39.3% | -1.3% | -9.9% | -43.8% | -56.1% | -20.4% | |
| P/FCF | 18.27 | 19.88 | 11.72 | 10.81 | 5.40 | 65.40 | 7.79 | 27.88 | 25.95 | — | 20.17 | — | 15.46 | 115.97 | 15.65 | 21.17 | 18.68 | — | 24.64 | 19.03 | 40.90 |
| — | -69.6% | +50.5% | -61.2% | -79.2% | — | -61.4% | — | +67.9% | — | +28.8% | — | -17.3% | — | -36.5% | +11.2% | -54.3% | — | — | -29.0% | -23.5% | |
| EV / EBITDA | 14.45 | 13.25 | 11.04 | 11.95 | 8.44 | 13.62 | 12.75 | 13.72 | 15.49 | 18.67 | 25.60 | 18.26 | 21.45 | 15.84 | 23.32 | 17.10 | 15.58 | 19.08 | 22.86 | 13.59 | 20.77 |
| — | -2.7% | -13.4% | -12.9% | -45.5% | -27.1% | -50.2% | -24.8% | -27.8% | +17.9% | +9.8% | +6.8% | +37.7% | -17.0% | +2.0% | +25.8% | -25.0% | -56.6% | -98.9% | -46.5% | +47.2% | |
| EV / EBIT | 23.76 | 23.56 | — | 17.01 | 13.78 | 17.33 | 14.36 | 18.27 | 20.98 | 25.23 | 25.39 | 21.51 | 29.42 | 22.60 | 25.51 | 26.38 | 23.32 | 32.83 | 27.89 | 22.94 | 42.58 |
| — | +36.0% | — | -6.9% | -34.3% | -31.3% | -43.4% | -15.1% | -28.7% | +11.6% | -0.5% | -18.5% | +26.1% | -31.1% | -8.5% | +15.0% | -45.2% | — | -41.4% | -42.2% | -0.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.7% | 59.8% | 57.2% | 56.5% | 56.0% | 59.7% | 55.0% | 57.4% | 55.3% | 53.3% | 55.0% | 55.0% | 53.6% | 53.8% | 54.0% | 52.0% | 53.1% | 54.3% | 58.2% | 53.3% | 51.2% |
| — | +0.1% | +4.0% | -1.6% | +1.3% | +11.9% | -0.0% | +4.3% | +3.2% | -0.9% | +2.0% | +5.8% | +1.0% | -1.0% | -7.2% | -2.4% | +3.7% | +12.5% | +17.7% | +6.5% | +1.6% | |
| Operating Margin | 18.1% | 16.9% | 14.9% | 20.5% | 20.6% | 16.8% | 15.6% | 16.9% | 15.0% | 11.8% | 8.7% | 13.7% | 11.1% | 17.2% | 11.6% | 14.2% | 15.7% | 11.8% | 7.2% | 13.7% | 10.2% |
| — | +1.0% | -4.6% | +21.2% | +37.4% | +41.7% | +78.5% | +23.9% | +34.9% | -31.4% | -24.7% | -3.5% | -29.4% | +46.5% | +59.9% | +3.3% | +53.8% | +1834.8% | +177.0% | -18.4% | -63.6% | |
| Net Margin | 7.3% | 9.7% | -5.8% | 13.2% | 11.8% | 10.6% | 17.5% | 10.8% | 9.8% | 11.4% | 5.9% | 9.3% | 7.8% | 13.2% | 9.7% | 10.8% | 11.2% | 7.6% | 3.7% | 8.9% | 6.2% |
| — | -8.1% | -133.2% | +22.7% | +20.7% | -7.2% | +195.6% | +15.8% | +25.1% | -13.4% | -38.5% | -13.9% | -29.8% | +73.4% | +162.6% | +20.7% | +80.2% | +490.1% | +174.9% | -32.6% | -73.0% |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.0% | 4.0% | -2.4% | 5.1% | 4.5% | 4.0% | 6.7% | 4.2% | 3.8% | 4.1% | 2.1% | 3.4% | 2.8% | 4.9% | 3.7% | 4.4% | 4.4% | 2.6% | 1.3% | 3.3% | 2.2% |
| — | +1.1% | -135.2% | +21.0% | +17.8% | -2.9% | +213.6% | +23.5% | +33.8% | -15.7% | -41.9% | -22.3% | -36.0% | +86.5% | +180.1% | +34.7% | +105.0% | +513.7% | +186.5% | -29.3% | -71.3% | |
| ROA | 4.0% | 1.4% | -0.8% | 1.8% | 1.6% | 1.4% | 2.3% | 1.5% | 1.3% | 1.6% | 0.9% | 1.5% | 1.3% | 2.1% | 1.5% | 1.8% | 1.8% | 1.1% | 0.5% | 1.3% | 0.8% |
| — | +0.1% | -135.4% | +22.3% | +18.1% | -14.5% | +151.2% | -0.0% | +6.5% | -23.1% | -39.9% | -15.7% | -30.4% | +95.0% | +192.0% | +37.6% | +118.0% | +538.2% | +175.0% | -45.1% | -75.5% | |
| ROIC | 10.3% | 2.4% | 2.2% | 2.9% | 2.8% | 2.3% | 2.2% | 2.4% | 2.2% | 1.8% | 1.4% | 2.4% | 2.0% | 3.0% | 2.0% | 2.5% | 2.7% | 1.8% | 1.1% | 2.1% | 1.4% |
| — | +6.3% | +0.0% | +20.0% | +30.0% | +28.7% | +55.4% | +3.9% | +8.1% | -41.9% | -30.7% | -4.7% | -25.0% | +71.3% | +78.3% | +18.3% | +86.6% | +2122.0% | +177.0% | -41.6% | -72.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.54 | 1.40 | 1.54 | 1.34 | 1.44 | 1.39 | 1.49 | 1.35 | 1.39 | 1.35 | 0.84 | 0.92 | 0.85 | 0.88 | 0.94 | 0.99 | 1.12 | 1.00 | 1.04 | 1.06 | 1.12 |
| — | +1.0% | +3.1% | -0.5% | +3.5% | +2.7% | +77.3% | +46.3% | +63.4% | +52.8% | -10.1% | -6.6% | -24.0% | -11.5% | -10.1% | -7.1% | +0.4% | -13.7% | -2.1% | +146.9% | +60.9% | |
| Debt / EBITDA | 3.08 | 13.88 | 15.55 | 12.63 | 12.82 | 14.82 | 15.37 | 13.91 | 15.14 | 17.76 | 16.49 | 12.52 | 13.04 | 9.99 | 15.13 | 11.47 | 11.60 | 14.57 | 18.95 | 12.95 | 15.11 |
| — | -6.3% | +1.1% | -9.2% | -15.3% | -16.5% | -6.8% | +11.1% | +16.1% | +77.7% | +9.0% | +9.2% | +12.4% | -31.4% | -20.1% | -11.4% | -23.2% | -57.7% | -98.2% | +155.8% | +167.5% | |
| Current Ratio | 2.95 | 3.08 | 2.95 | 1.75 | 1.64 | 1.72 | 1.62 | 3.97 | 3.49 | 3.76 | 2.56 | 2.92 | 3.28 | 3.38 | 3.06 | 3.11 | 2.73 | 3.81 | 1.71 | 2.05 | 2.42 |
| — | +79.3% | +82.7% | -56.0% | -53.0% | -54.3% | -36.8% | +35.9% | +6.5% | +11.2% | -16.3% | -6.1% | +20.0% | -11.2% | +78.8% | +51.7% | +12.6% | +27.1% | -37.5% | -40.3% | +7.9% | |
| Quick Ratio | 1.87 | 1.91 | 1.87 | 1.15 | 1.03 | 1.04 | 0.99 | 2.55 | 2.09 | 2.33 | 1.50 | 1.76 | 2.19 | 2.16 | 2.03 | 1.99 | 1.76 | 2.27 | 1.05 | 1.19 | 1.31 |
| — | +84.1% | +89.7% | -54.8% | -50.9% | -55.3% | -34.5% | +44.9% | -4.6% | +7.5% | -25.8% | -11.3% | +24.8% | -4.8% | +93.6% | +66.6% | +34.7% | +44.9% | -28.5% | -37.1% | -2.9% | |
| Interest Coverage | 5.46 | 4.81 | -4.28 | 8.38 | 8.11 | 15.94 | — | 7.26 | 8.55 | — | 7.57 | 30.27 | 17.25 | 25.93 | 17.59 | 41.06 | 8.30 | 5.83 | 8.72 | 8.34 | 5.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HAE stock.
Haemonetics Corporation's current P/E is 51.1x. The average P/E over the last 3 quarters is 20.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Haemonetics Corporation's current operating margin is 18.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Haemonetics Corporation's business trajectory between earnings reports.